

Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma

Antonio TEJERA-VAQUERIZO^{1,2}, Sabela PARADELA³, Agustí TOLL⁴, Jorge SANTOS-JUANES⁵, Ane JAKA⁶, Alba LÓPEZ⁷, Javier CAÑUETO⁸, Álvaro BERNAL⁹, Isabel VILLEGAS-ROMERO¹⁰, Carla FERRÁNDIZ-PULIDO¹¹, Héctor PERANDONES¹², David MORENO-RAMÍREZ¹³, Carolina DOMÍNGUEZ-MAHAMUD¹⁴, Rafael SALIDO-VALLEJO¹⁵, Onofre SANMARTÍN¹⁶, Francisco M. ALMAZÁN-FERNÁNDEZ¹⁷, Pedro RODRÍGUEZ-JIMÉNEZ¹⁸, José BAÑULS^{19,20}, Sebastian PODLIPNIK⁴, Alejandra SANDOVAL-CLAVIJO^{4,21}, Aram BOADA⁶, Beatriz GARCÍA-BRACAMONTE⁷, Sara PALENCIA⁷, David REVILLA-NEBREDAS⁸, Enara REOLARAMÍREZ⁹, María del Carmen GÓMEZ-MATEO⁹, Mario LINARES-BARRIOS¹⁰, David JIMÉNEZ-GALLO¹⁰, Carlos GONZÁLEZ-CRUZ¹¹, Elia SAMANIEGO¹², María NAVEDO-DE LAS HERAS¹², Rosa TABERNER¹⁴, Teresa RÓDENAS-HERRANZ¹⁷, Carmen GARCÍA-DONOSO⁷, Susana PUIG⁴ and Eduardo NAGORE¹⁶

¹Dermatology Department, Dermatologic Institute GlobalDerm, Palma del Río (Córdoba), ²Unit of Cutaneous Oncology, Hospital San Juan de Dios, Córdoba, ³Dermatology Department, Complejo Hospitalario Universitario A Coruña, Coruña, ⁴Dermatology Department, Hospital Clínic of Barcelona, Barcelona, ⁵Dermatology Department, Central University Hospital of Asturias and Instituto de Investigación Sanitaria of Principado de Asturias, IUOPA, Oviedo University, Oviedo, ⁶Dermatology Department, University Hospital Germans Trias i Pujol, Badalona, Barcelona, ⁷Dermatology Department, University Hospital 12 de Octubre, Madrid, ⁸Dermatology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, ⁹Unit of Cutaneous Tumors, University Hospital Miguel Servet, Zaragoza, ¹⁰Dermatology Department, University Hospital Puerta del Mar, Cadiz, ¹¹Dermatology Department, University Hospital Vall d'Hebron, Barcelona, ¹²Dermatology Department, University Hospital of León, León, ¹³Melanoma Unit, Dermatology Department, University Hospital Virgen Macarena, Sevilla, ¹⁴Dermatology Department, University Hospital Son Llàtzer, Mallorca, ¹⁵Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, ¹⁶Dermatology Department, Instituto Valenciano de Oncología, Valencia, ¹⁷Dermatology Department, University Hospital San Cecilio, Granada, ¹⁸Dermatology Department, University Hospital La Princesa, Madrid, ¹⁹Dermatology Department, General University Hospital, Alicante, ²⁰Dermatology Area, Clinical Medicine Department, University Miguel Hernandez, Sant Joan de Alicante, Spain, and ²¹Department of Dermatology, Fundación Universitaria Sanitas, Bogotá-Colombia

The aim of this study was to compare tumour burden in patients who underwent surgery for melanoma and cutaneous squamous cell carcinoma during nationwide lockdown in Spain due to COVID-19 (for the period 14 March to 13 June 2020) and during the same dates in 2019 before the COVID-19 pandemic. In addition, associations between median tumour burden (Breslow thickness for melanoma and maximum clinical diameter for cutaneous squamous cell carcinoma) and demographic, clinical, and medical factors were analysed, building a multivariate linear regression model. During the 3 months of lockdown, there was a significant decrease in skin tumours operated on (41% decrease for melanoma ($n = 352$ vs $n = 207$) and 44% decrease for cutaneous squamous cell carcinoma ($n = 770$ vs $n = 429$)) compared with the previous year. The proportion of large skin tumours operated on increased. Fear of SARS-CoV-2 infection, with respect to family member/close contact, and detection of the lesion by the patient or doctor, were related to thicker melanomas; and fear of being diagnosed with cancer, and detection of the lesion by the patient or relatives, were related to larger size cutaneous squamous cell carcinoma. In conclusion, lockdown due to COVID-19 has resulted in a reduction in treatment of skin cancer.

Key words: melanoma; cutaneous squamous cell carcinoma; delay; surgery; COVID-19; SARS-CoV-2.

Accepted Aug 13, 2021; Epub ahead of print Aug 16, 2021

Acta Derm Venereol 2021; 101: adv00525.

Corr: Antonio Tejera-Vaquerizo, Dermatology Department, Dermatologic Institute GlobalDerm, Palma del Río (Córdoba), Spain. E-mail: antonio-tejera@aedv.es

SIGNIFICANCE

There is little evidence regarding the impact of COVID-19 lockdown on skin tumour burden. The COVID-19 lockdown resulted in a reduction in surgery for melanoma and cutaneous squamous cell carcinoma and an increase in the proportion of tumours with a worse prognosis. The increase was due to patient-dependent factors; in particular, fear of SARS-CoV-2 infection. Therefore, health education programmes targeting the general population are needed to ensure the prompt treatment of patients with skin cancer.

The coronavirus disease 19 (COVID-19) pandemic, which started in Wuhan, China in December 2019 (1), led to a massive lockdown in Spain and many other countries. Disruptions to healthcare services during this time have raised questions about possible delays in skin cancer treatment. A recent study of the estimated effect of diagnostic delays due to lockdown on tumour size in melanoma and cutaneous squamous cell carcinoma (cSCC), using a tumour growth model, showed that there was a significant increase in the proportion of tumours with a poor prognosis (1, 2). Nonetheless, the true effects of lockdown on skin cancer and the reasons for delayed treatment are unknown. The aims of this study were to analyse the effects of lockdown on tumour burden (thickness and diameter) in melanoma and cSCC, and to investigate factors associated with thicker or larger tumours.

MATERIALS AND METHODS

A multicentre observational study was performed of all consecutive patients who underwent surgery for melanoma or cSCC at

18 referral hospitals for skin cancer in different regions of Spain between 14 March 2020, the start of a nationwide lockdown due to COVID-19, and 13 June 2020, the end of lockdown. Patients treated during the same period in 2019 were selected as controls. The study was approved by the ethics committee at Hospital Universitario Reina Sofía de Córdoba (reference 4682).

Study variables

Patient age and sex were recorded, analysing changes in tumour burden of patients during lockdown in 2020 and the same period from 2019. For melanomas, information was collected on Breslow thickness (stratified according to the American Joint Committee on Cancer (AJCC) staging system (4)), the presence or absence of ulceration, and clinicopathological stage. For cSCCs, clinical diameter was recorded (classified as <20, 20–40, or >40 mm, as recommended by the AJCC (4)) and clinical stage. This information was obtained from the pathology reports at the participating hospitals.

To analyse factors associated with greater tumour burden following lockdown, a standardized questionnaire was administered in person (Appendix S1¹) to patients who attended each centre and who consented to participate. The following data were collected:

- **Demographic characteristics:** age, sex, level of education (no schooling, primary, secondary, university), residence in an urban, rural, or in-between area (>10,000, <2,000, or 2,000–10,000 inhabitants, respectively, as per the Spanish National Institute of Statistics), (5) and usual place of residence (private home vs nursing home).
- **Medical history:** personal and family history of skin cancer.
- **Skin cancer awareness and behaviour:** level of skin cancer awareness (non-existent, low, moderate, high), having seen or heard skin cancer campaign messages or news during lockdown, skin self-examination in the past year, skin examination by a doctor in the past year, person who detected the tumour (patient, family member/close contact, doctor), and tumour location (visible vs hidden usually by clothes).
- **Reasons for delayed treatment:**
 - **Patient-related reasons:** belief that their lesion was benign, fear of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), fear of being diagnosed with cancer.
 - **Medical reasons:** misdiagnosis by a doctor, delay in getting an appointment with a dermatologist (<2 weeks, 2 weeks to 2 months, >2 months), delay in surgery (<2 weeks, 2 weeks to 2 months, >2 months), time to reopening of surgical activity after lockdown (surgical activity was not closed, <1 month, >1 month).

Statistical analysis

Differences between 2020 and 2019. Differences were analysed using the χ^2 test and or the t-test, as appropriate.

Factors associated with greater tumour burden. Because the distributions of Breslow and diameter were skewed, logarithmic transformation was performed to construct the data as normal. Normality of distribution was checked using the Kolmogorov–Smirnov test and visual assessment. Patients with melanoma *in situ* were excluded from this analysis as it is impossible to transform zero values. To explore univariate factors potentially associated with tumour burden, differences in thickness and diameter were analysed, and the results for the different categories of each study variable were compared. Results were compared using the non-parametric Mann–Whitney *U* and Kruskal–Wallis

tests for 2 or 3 or more categories, respectively. Variables that were significant ($p < 0.1$) in the univariate analysis were used to fit a linear regression model (with the log-transformed dependent variables) using a forward stepwise selection approach, in which variables with a significance level of $p > 0.1$ were excluded and included again if $p < 0.05$ to build a multivariate linear regression model for log-transformed thickness and diameter values. The variables were analysed by groups (medical causes–medical history–cancer awareness vs reasons for delay). Those that were significant ($p < 0.05$) in the multivariate analysis of each group were included in a combined multivariate analysis. Regression coefficients were calculated with 95% confidence intervals (95% CIs). Analyses were performed in SPSS (Version 21.0. IBM Corp., Armonk, NY, USA).

RESULTS

Comparison of 2019 and 2020

The number of melanomas treated during the periods analysed decreased from 352 in 2019 to 207 in 2020 (41% reduction) (Table I). The proportions of men and women was 44.3% and 55.7% in 2019, and 57.5% and 42.5% in 2020 ($p = 0.003$). The number and percentage of different Breslow thicknesses also varied significantly

Table I. Comparison of clinicopathological characteristics of melanoma and cutaneous squamous cell carcinoma during the 2020 COVID-19 lockdown and the same period in 2019

	2019 (March 14–June 13) ^a	2020 (March 14–June 13) ^a	<i>p</i> -value
Melanoma			
Sex, <i>n</i> (%)			
Male	156 (44.3)	119 (57.5)	0.003
Female	196 (55.7)	88 (42.5)	
Age, years, mean \pm SD	64 \pm 16.4	62.9 \pm 16.7	0.45
Ulceration, <i>n</i> (%)			
Present	49 (13.9)	41 (20)	0.06
Absent	303 (86.1)	164 (80)	
Thickness, mm, <i>n</i> (%)			
<i>In situ</i>	123 (34.9)	60 (29)	0.05
<0.8	75 (21.3)	43 (20.8)	
0.8–1.0	34 (9.7)	12 (5.8)	
>1.0–2.0	43 (12.2)	30 (14.5)	
>2.0–4.0	41 (11.6)	24 (11.6)	
>4.0	36 (10.2)	38 (18.4)	
Clinical stage, <i>n</i> (%)			
0	123 (34.9)	60 (29)	0.001
I	139 (39.7)	76 (36.7)	
II	64 (18.2)	51 (24.6)	
III	20 (5.7)	17 (8.2)	
IV	6 (1.7)	3 (1.4)	
Total, <i>n</i>	352	207	
Cutaneous squamous cell carcinoma			
Sex, <i>n</i> (%)			
Male	520 (67.5)	273 (63.6)	0.2
Female	250 (32.5)	156 (36.4)	
Age, years, mean \pm SD	79.8 \pm 10.9	79 \pm 11.3	0.2
Diameter, mm, <i>n</i> (%)			
≤ 20	609 (81.1)	294 (68.9)	<0.001
>20 to ≤ 40	117 (15.6)	108 (25.3)	
>40	25 (3.3)	25 (5.9)	
Clinical stage			
I	578 (70.1)	234 (54.5)	<0.001
II	91 (11.9)	61 (14.2)	
III	128 (16.7)	127 (29.6)	
IV	10 (1.3)	7 (1.6)	
Total, <i>n</i>	770	429	

^aVariations in total number of patients in each category are due to missing data. SD: standard deviation.

¹<https://doi.org/10.2340/00015555-3890>

from 2019 to 2020, with a reduction in melanomas in situ ($n=123$ (34.9%) vs $n=60$ (29%)) and a slight increase in thick melanomas (>4 mm) ($n=36$ (10.2%) vs $n=38$ (18.4%)) ($p=0.05$). Thus, the most relevant changes in clinicopathological stages were observed for stage 0 melanoma. There were also changes in stage II melanoma ($n=64$ (18.2%) vs $n=51$ (24.6%)) ($p=0.001$), and stage III melanoma ($n=20$ (5.7%) vs $n=17$ (8.2%)). No significant change was observed for stage IV melanoma.

The number of cSCCs treated decreased by 44%, from 770 cases in 2019 to 429 in 2020 (Table I). In this case, however, there was no change in the proportions of men and women. The mean age of patients was similar in both periods. The number of cSCCs measuring <20 mm decreased from 609 (81.1%) in 2019 to 294 (68.9%) in 2020, but there was an increase in the

proportions of tumours measuring 20–40 mm ($n=117$ (15.6%) vs $n=108$ (25.3%)) and >40 mm ($n=25$ (3.3%) vs $n=25$ (5.9%)) ($p<0.001$). A reduction in stage I cSCCs ($n=578$ (70.1%) vs $n=234$ (54.5%)) and a proportional increase in stage II ($n=91$ (11.9%) vs $n=61$ (14.2%)) and stage III ($n=128$ (16.7%) vs $n=127$ (29.6%)) cSCCs were also observed. As with melanoma, no significant changes were observed for stage IV tumours. The differences between stages were statistically significant ($p<0.001$)

Factors associated with tumour burden

Melanoma. Of the 207 patients who underwent melanoma surgery between the start and end of lockdown, 147 (71%) completed the questionnaire. There was no

Table II. Demographic characteristics and tumour burden in patients with invasive melanoma or cutaneous squamous cell carcinoma during the COVID-19 lockdown in Spain

Variable	Melanoma patients					Cutaneous squamous cell carcinoma patients				
	n*	Univariate analysis		Multivariate analysis		n*	Univariate analysis		Multivariate analysis	
		Thickness, mm Median (IQR)	p-value	Coefficient 95% CI	p-value		Diameter, mm Median (IQR)	p-value	Coefficient 95% CI	p-value
Age, years, mean (SD)	100	66 (15.6)	0.001	1.01 (1.001–1.03)	<0.001	320	81 (12)	0.001	1.01 (1.005–1.02)	0.002
Sex										
Male	56	1.9 (0.6–5)		NA		207	15 (10–25)		NA	
Female	44	1.3 (0.6–4)	0.54			113	15 (10–22)	0.5		
Usual residence										
Private home	97	1.4 (0.6–4)	0.01	1	0.03	298	15 (10–22)	0.006	1	0.001
Nursing home	3	7 (7–NA)		4 (1.1–14.1)		17	25 (15–44)		2 (1.1–3.4)	
Education										
No schooling	4	7.7 (2.1–13.3)	0.07	NS		52	15 (10–25)	0.4	NS	
Primary studies	46	1.3 (0.6–3.7)				163	15 (10–23)			
Secondary studies	25	2.6 (1.1–5.5)				57	15 (7.5–25)			
University education	25	0.8 (0.5–3.1)				35	12 (10–26)			
Area										
Rural	4	5.6 (2.3–7.1)	0.05	NS		23	19 (10–25)	0.5	NS	
In-between (rural and urban)	16	2.3 (1.3–4.7)				43	15 (10–30)			
Urban	80	1.2 (0.5–4)				252	15 (10–24)			
Personal history of skin cancer										
No	81	1.8 (0.6–4.7)	0.16	NA		139	15 (10–22)	0.9	NA	
Yes	19	1.1 (0.5–2.5)				176	15 (10–25)			
Family history of skin cancer										
No	86	1.9 (0.6–4.7)	0.19	NA		228	15 (10–25)	0.3	NA	
Yes	14	0.9 (0.5–3.2)				78	15 (9–25)			
Level of awareness about skin cancer										
None	29	2 (0.7–5)	0.38	NA		102	16.5 (10–26.3)	0.3	NA	
Low	38	2.1 (0.6–5)				137	15 (10–21.5)			
Medium	24	1 (0.5–2.9)				60	14 (10–22)			
High	9	0.9 (0.6–2.7)				16	16 (10–25)			
Seen/heard skin cancer campaign messages or news during lockdown										
No	93	1.5 (0.6–4.6)	0.9	NA		294	15 (10–25)	0.04	NA	
Yes	7	0.9 (0.6–4.6)				7	12.5 (6.5–29)			
Skin self-examination in past year										
No	64	2.2 (0.7–5.1)	0.003	1	0.01	164	15 (10–25)	0.2	NA	
Yes	34	1 (0.5–1.9)		0.6 (0.4–0.9)		113	14 (10–22)			
Skin examination by physician in past year										
No	64	1.9 (0.6–5)	0.06	NS		125	15 (10–25)	0.5	NA	
Yes	34	1.1 (0.5–3.3)				159	15 (10–22)			
Detected by										
Patient	59	1.9 (0.6–4.8)	0.001	1		170	15 (10–25)	0.03	1	
Family member/close contact	21	0.6 (0.4–1.9)		0.4 (0.2–0.7)	0.002	65	17 (11–24)		0.9 (0.8–1.4)	0.5
Doctor	19	2.8 (1.2–7)		1.4 (0.7–2.4)	0.2	71	14 (8–29)		0.8 (0.7–0.9)	0.004
Hidden area										
No	93	1.5 (0.7–4.7)	0.8	NA		300	NC		NC	
Yes	7	2.5 (0.3–4.1)				0	NC		NC	

95% CI: 95% confidence interval; IQR: interquartile range (25th–75th percentile); NA: not applicable; NC: not calculable; NS: non-significant.

*Variations in the total number of patients in each category are due to missing data.

Table III. Patient-related and medical reasons for delays in treatment and tumour burden in invasive melanomas and cutaneous squamous cell carcinomas during COVID-19 lockdown

Variable	n*	Melanoma patients				Cutaneous squamous cell carcinoma patients			
		Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
		Median (IQR) mm	p-value	Coefficient (95% CI)	p-value	Median (IQR) mm	p-value	Coefficient (95% CI)	p-value
<i>Patient-related reasons for delays</i>									
Belief lesion was benign									
No	50	1.5 (0.6–4.2)	0.8	NA		235	15 (10–35)	0.4	NA
Yes	50	1.8 (0.6–4.8)				85	15 (10–21.5)		
Fear of infection with SARS-CoV-2									
No	88	1.3 (0.6–4)	0.006	1	0.005	264	15 (10–25)	0.9	
Yes	12	4.3 (1.5–14.3)		2.8 (1.7–5.6)		56	15 (10–23)		
Fear of being diagnosed with cancer									
No	97	1.5 (0.6–4.3)	–	NA		312	15 (10–22)	<0.001	1
Yes	3	4.8 (1.4–NA)				8	32.5 (30–57)		2.5 (1.6–3.9)
<i>Medical reasons for delays</i>									
Misdiagnosis by a doctor									
No	85	1.6 (0.6–4.7)	0.3	NA		294	15 (10–22)	0.5	NA
Yes	15	1.4 (0.4–3.2)				19	19 (7.5–35)		
Delay in getting appointment with dermatologist									
< 2 weeks	42	1.9 (0.6–4.8)	0.6	NA		102	14 (8–20)	0.04	NS
2 weeks to 2 months	13	0.8 (0.4–4.5)				86	16.5 (11.8–25)		
> 2 months	22	1.4 (0.9–5.7)				71	15 (10–28)		
Surgical delay									
< 2 weeks	50	1.8 (0.8–3.4)	0.4	NA		115	15 (10–22)	0.5	NA
2 weeks to 2 months	28	2.2 (0.6–5.4)				110	14 (10–25)		
> 2 months	22	0.75 (0.4–5.6)				98	15 (10–25)		
Reopening of surgery									
Not closed	39	1.4 (0.6–4.6)	0.8	NA		113	14 (10–22)	0.003	NS
< 1 month	11	1.9 (0.5–4.8)				28	22 (15–39)		
> 1 month	50	1.5 (0.6–4.6)				179	15 (10–24)		

95% CI: 95% confidence interval; IQR: interquartile range (25th–75th percentile); NA: not applicable; NS: non-significant.

*Variations in total number of patients in each category is due to missing data.

difference in the median of Breslow and age for non-responded and responded patients to questionnaire (data not shown). Of these, only those with invasive melanoma ($n=100$) were analysed to investigate factors associated with tumour burden (see Methods). The univariate analysis showed a significant association between age and Breslow thickness (Table II). Other factors associated with a greater median thickness were living in a nursing home, no schooling, living in a rural area, non-performance of skin self-examination or by a doctor in the past year, and detection of the tumour by a doctor. Multivariate analysis of these variables confirmed that living in a nursing home vs a private home was associated with greater median Breslow thickness (4.95; 95% CI: 1.1, 14.1; $p=0.03$), while performance vs non-performance of a self skin-examination (0.6; 95% CI: 0.4, 0.9; $p=0.01$) and detection of the lesion by a family member/close contact vs the patient (0.4; 95% CI: 0.2, 0.7; $p<0.002$) were associated with lower median thickness.

Among the reported reasons for delays, only fear of infection with SARS-CoV-2 was associated with greater Breslow thickness in both the univariate and multivariate analyses (2.8; 95% CI: 1.7, 5.6; $p=0.005$) (Table III).

In the combined multivariate analysis, age (as a continuous variable) (1.01; 95% CI: 1.005, 1.03; $p=0.01$), living in a nursing home (3.4; 95% CI: 1, 12; $p=0.05$), detection of the lesion by a family member/close contact

(0.5; 95% CI: 0.3, 0.8; $p=0.007$), and fear of infection with SARS-CoV-2 (2.2; 95% CI: 1.2, 2.4; $p=0.02$) were all associated with Breslow thickness. The R^2 of the model was 0.3 (Table IV).

Squamous cell carcinoma. Of the 429 patients who underwent surgery for cSCC between the start and end of lockdown, 323 (75.2%) completed the study questionnaire. There was no difference in the median of diameter of tumours and age for non-responded and responded patients to questionnaire (data not shown). The univariate analysis showed a significant association between a larger tumour diameter and age, living in a nursing home, and not having seen or heard skin cancer campaign messages

Table IV. Combined multivariate analysis of factors associated with melanoma thickness

Variable	Coefficient (95% CI)	p-value
Age (continuous)	1.01 (1.005–1.03)	0.01
Usual residence		
Private home	1	
Retirement home	3.4 (1–12)	0.05
Detected by		
Patient	1	
Family member/close contact	0.5 (0.3–0.8)	0.007
Doctor	1.4 (0.8–2.4)	0.2
Fear of infection with SARS-CoV-2		
No	1	0.02
Yes	2.2 (1.2–2.4)	
		$R^2=0.3$

CI: confidence interval; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

or news during lockdown (Table II). Detection of the tumour by a doctor, by contrast, was associated with a smaller diameter. Multivariate analysis confirmed that age (1.01; 95% CI: 1.005, 1.02; $p=0.002$), living in a nursing home vs a private home (2; 95% CI: 1.1, 3.3; $p=0.001$), and diagnosis by a doctor vs detection by the patient (0.8; 95% CI: 0.7, 0.9; $p=0.004$) were associated with cSCC diameter.

Among the reasons reported for delays, fear of being diagnosed with cancer, a delay of over 2 weeks in getting an appointment with a dermatologist, and reopening of surgical activities within one month were associated with a larger diameter. The only factor that retained its significance in the multivariate analysis was fear of being diagnosed with cancer (2.5; 95% CI: 1.6, 3.9; $p<0.001$) (Table III).

In the combined multivariate analysis, age (as a continuous variable) (1.01; 95% CI: 1.2, 1.02; $p=0.03$), living in a nursing home (1.7; 95% CI: 1, 2.3; $p=0.02$), detection by a doctor (0.8; 95% CI: 0.7, 0.9; $p=0.006$), and fear of infection with SARS-CoV-2 (2.2; 95% CI: 1.4, 3.6; $p=0.06$) were all predictors of cSCC diameter. The R^2 of the model was 0.11 (Table V).

DISCUSSION

The main finding of this study is that the nationwide lockdown imposed in Spain due to the COVID-19 pandemic resulted in a reduction in the number of patients who underwent surgery for melanoma or cSCC and an increase in the proportion of thicker and larger tumours operated on.

During the lockdown Spanish citizens were required to remain in their homes for a mean of 6 weeks, starting on 14 March 2020. The health authorities ruled that all non-deferrable procedures, including cancer treatments, should continue as normal, and that primary care activity, specialist visits, and hospital consultations should be reduced to the minimum to prevent these centres from becoming foci of infection. In addition, surgical activity was either cancelled or drastically reduced in order to redirect all necessary resources to the care of patients

with COVID-19. The sum of these actions, combined with variable reopening times for the different public healthcare services, resulted in fewer skin cancer surgeries and a greater proportion of thick melanomas and large cSCCs.

Three societies have published recommendations for the management and treatment of skin tumours in the context of the current COVID-19 pandemic. With regard to melanoma, the National Comprehensive Cancer Network (NCCN) recommends a delay of up to 3 months in T0 and T1 cases, even if the margins are affected. However, it mentions the possibility of excision of up to 1 cm in cases of in situ/invasive melanoma if possible (3). This 1-stage management of in situ or thin invasive melanomas was beginning to gain acceptance in our country before the SARS-Cov-2 pandemic in an attempt to simplify the management of melanomas (4, 5). The British Association of Dermatologists and the British Society for Dermatological Surgery (6) have made similar recommendations for delay in the management of thin or in situ melanomas. With respect to SCC, the recommendations of these societies are similar with respect to SCC in situ or of the well-differentiated histological variety, with a recommendation for a delay of 2–3 months if necessary. Logically, fast-growing, symptomatic or ulcerated tumours, or tumours with perineural invasion or poorly differentiated tumours, especially in immunocompromised patients, should be prioritized (7).

A number of recent studies have reported a significant reduction in the treatment of melanoma at Italian hospitals during lockdown in Italy (8, 9) According to a recent study by our group, which modelled tumour growth based on the kinetics of melanoma and cSCC (2), a diagnostic delay of 2 months would result in a doubling of the proportion of thick melanomas (>4 mm) and a 60% increase in that of large cSCCs (>40 mm). The current study also observed a doubling of the proportion of thick melanomas (18.4% in 2020 vs 9.3% in 2019), despite the 41% reduction in the number of cases. Similarly, despite a 47% reduction in the number of cSCCs treated, the number of large tumours (>40 mm) was the same in 2019 and 2020. In this case, however, the proportion of large cSCCs (3.3% vs 5.9%) and stage III cSCCs doubled (16.7% vs 29.6%). While the current findings appear to indicate that a considerable proportion of patients with skin tumours with a worse prognosis received care as usual, they also suggest that we can expect to see an increase in cases with a worse prognosis in the coming months, as more than a third of patients who would usually have been seen during the study period were not.

It is worth mentioning that the melanoma group that has decreased the most is that of melanomas in situ, while invasive melanomas have increased proportionally. This could indicate that, over a period of months, melanomas *in situ* can become invasive in many cases.

Table V. Combined multivariate analysis of factors associated with cutaneous squamous cell carcinoma diameter

Variable	Coefficient (95% CI)	<i>p</i> -value
Age (continuous)	1.01 (1.005–1.02)	0.03
Usual residence		
Private home	1	0.002
Nursing home	1.7 (1.2–2.3)	
Detected by		
Patient	1	
Family member/close contact	0.9 (0.8–1.2)	0.6
Doctor	0.8 (0.7–0.9)	0.006
Fear of being diagnosed with cancer		
No	1	0.006
Yes	2.2 (1.4–3.6)	
		$R^2=0.11$

95% CI: 95% confidence interval.

Age was associated with thicker melanomas and larger cSCCs, particularly in the subgroup of nursing home residents, although this group was small. Older age is a known risk factor for thicker skin tumours, as well as a predictor of poor prognosis (8, 9). Nevertheless, because elderly patients with comorbidities are at the greatest risk of SARS-CoV-2 infection and its complications, they are much more likely to experience treatment delays (10). The dangers of neglecting melanoma during the COVID-19 pandemic have already been highlighted (11).

One important finding of the current study is that of all the possible reasons for treatment delays analysed, fear of infection with SARS-CoV-2 was the only factor associated with greater melanoma thickness. Widespread fear of COVID-19 and its consequences among the general public is already recognized in the literature (12).

Fear of being diagnosed with cancer was associated with larger size cSCCs. Cancer fears are relatively common in the general population and can lead to avoidance behaviours and delays in seeking care (13). In some cases, this behaviour has been associated with the diagnosis of large tumours (14).

Compared with tumours detected by the patient, melanomas detected by a family member/close contact were more likely to be thinner, while cSCCs detected by a doctor were more likely to be smaller. The findings of the current study support reports that melanoma thickness at diagnosis varies according to the person who detected the lesion (15).

Although patients with cSCC in hidden part of the body have been found to be more likely to have large tumours, this was not the case in the current study.

Finally, despite the organizational changes implemented at each of the study hospitals, none of the medical reasons for delayed surgery (misdiagnosis by a doctor, delays in getting an appointment with a dermatologist, surgical delays, or time to reopening of surgical activity) was associated with tumour burden.

The main strength of the current study is that it is a multicentre study of referral hospitals for skin cancer in different regions of Spain. In addition, the fact that the analysis was based on general demographic and clinical variables and not on specific factors will have reduced the risk of bias.

A limitation of the current study is that it analysed only the first 3 months of lockdown, and therefore may have underestimated the effect of disruptions to healthcare services on tumour burden. Since melanoma and cSCC incidence rates do not vary substantially from year to year, it is likely that more patients than usual will present with larger-than-expected tumours in the coming months. A further limitation is that it is not a randomized sample.

In conclusion, this study showed that there was a reduction in the number of melanomas and cSCCs treated in the 3 months of nationwide lockdown in Spain, as well as an increase in the proportion of tumours with a poor prognosis.

In the case of melanoma, patient-related factors, such as age, living in a nursing home, and fear of infection with SARS-CoV-2, were associated with greater Breslow thickness, while detection of lesions by a family member/close contact was associated with lower thickness. In the case of cSCC, age, living in a nursing home, and fear of being diagnosed with cancer were associated with a larger diameter, while detection of the tumour by a doctor was associated with a smaller diameter. None of the medical reasons for delay were associated with greater tumour burden.

Fear of infection with SARS-CoV-2 and of being diagnosed with cancer were both predictors of tumours with a worse prognosis. As these are modifiable factors, they should be included in skin cancer awareness and screening programmes.

ACKNOWLEDGEMENTS

The authors thank M. A. Descalzo-Gallego from the Research Unit of the Spanish Academy of Dermatology and Venereology (AEDV) for reviewing the study methodology and statistical analyses, and the pathology laboratories at the different hospitals for helping to identify cases.

Reviewed and approved by Hospital Reina Sofia de Córdoba IRB; approval #4682.

The current study was presented at the European Academy of Dermatology and Venereology (EADV) 2020 congress.

Conflicts of interest: CG-D reports other from Lilly, grants and other from Novartis, outside the submitted work. SP reports grants and other from Amgen, personal fees and other from Avane, other from Abbvie, grants, personal fees, non-financial support and other from Almirall, personal fees from BSM, grants, personal fees and non-financial support from ISDIN, grants, personal fees and non-financial support from La Roche Posay, grants, personal fees and non-financial support from Leo Pharma, non-financial support from MSD, personal fees and non-financial support from Pierre Fabre, personal fees and non-financial support from Pfizer, personal fees, non-financial support and other from Regeneron, grants, personal fees and non-financial support from Roche, personal fees and non-financial support from Sanofi, grants and personal fees from Sunpharma, grants from Castle, personal fees from Canfield, non-financial support from Lilly, non-financial support from Novartis, grants from Melagenix, outside the submitted work.

REFERENCES

1. Tejera-Vaquero A, Nagore E. Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. *J Eur Acad Dermatol Venereol* 2020; 34: e351–e353.
2. Tejera-Vaquero A, Cañueto J, Toll A, Santos-Juanes J, Jaka A, Ferrandiz-Pulido C, et al. Estimated effect of COVID-19 lockdown on skin tumor size and survival: an exponential growth model. *Actas Dermo-Sifiliograficas* 2020; 111: 629–638.
3. NCCN. Short-term Recommendations for Cutaneous Melanoma Management during COVID-19 Pandemic. Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community [accessed 7 Dec 2020]. Available from: <https://www.nccn.org/covid-19/pdf/Melanoma.pdf>.
4. Russo F. Current evidence of one-step surgical treatment in cutaneous melanoma. *Actas Dermosifiliogr* 2020; 111: 541–544.

5. Tejera-Vaquero A, Russo F, Nieto-González G. Skin lesion suspicious of melanoma: time to one-step removal. *J Prim Health Care* 2019; 11: 87.
6. British Association of Dermatologists & British Society for Dermatological Surgery COVID-19-Skin cancer surgery guidance. Clinical guidance for the management of skin cancer patients during the coronavirus pandemic [accessed 7 Dec 2020]. Available from: <http://www.bad.org.uk/healthcare>.
7. American College of Mohs Surgery: COVID-19 (Coronavirus) preparedness. COVID-19 (Coronavirus) Preparedness [accessed 7 Dec 2020]. Available from: <https://www.mohscollege.org/UserFiles/AM20/Member Alert/COVIDAlert3March20.pdf>.
8. Ricci F, Fania L, Paradisi A, Di Lella G, Pallotta S, Sobrino L, et al. Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. *J Eur Acad Dermatol Venereol* 2020; 34: e778–e779.
9. Barruscotti S, Giorgini C, Brazzelli V, Vassallo C, Michelerio A, Klersy C, et al. A significant reduction in the diagnosis of melanoma during the COVID-19 lockdown in a third-level center in the Northern Italy. *Dermatol Ther* 2020; 33: e14074.
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395: 507–513.
11. Gomolin T, Cline A, Handler MZ. The danger of neglecting melanoma during the COVID-19 pandemic. *J Dermatolog Treat* 2020; 31: 444–445.
12. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 scale: development and initial validation. *Int J Ment Health Addict* 2020 Mar 27. [Epub ahead of print].
13. Vrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, et al. What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. *Psycho-Oncology* 2017; 26: 1070–1079.
14. Block LM, Jee YM, Baskaya MK, Bentz ML, Poore SO. Denying the obvious: four extreme cases of neglected tumors. *Plast Reconstr Surg Glob Open* 2015; 3: e571.
15. Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. *J Am Acad Dermatol* 2016; 75: 967–974.